|
|
Vol. 16.18 – 26 September, 2025
|
|
|
|
|
|
|
|
Investigators developed a peptide-based proteolysis-targeting chimera (PROTAC) drug that specifically targets BRCA2, leading to its degradation in a DDB1-dependent manner. [Cancer Research]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Scientists demonstrated that ULK1 expression is positively correlated with both loss-of-function mutations in SPOP and the upregulation of the E3 ubiquitin ligase TRIM24 in human prostate cancer specimens.
[Cell Death & Differentiation]
|
|
|
|
|
|
Researchers revealed that CCDC719-13 expression is markedly reduced in advanced and recurrent prostate cancer, where its low levels serve as an independent predictor of poor prognosis. [Cell Death & Differentiation]
|
|
|
|
|
|
Scientists demonstrated that KBTBD11 E3 ubiquitin ligase gene is frequently deleted in human prostate cancers and that KBTBD11 loss augments AKT phosphorylation in prostate cancer cells in culture and in patient samples.
[Oncogene]
|
|
|
|
|
|
Using scRNA-sequencing and multiparametric flow-cytometry analysis, researchers comprehensively characterized immune cells in wild-type and PTEN(i)pe−/− mouse prostates, a model that closely recapitulates human prostate cancer.
[Oncoimmunology]
|
|
|
|
|
|
Investigators demonstrated that androgen deprivation therapy (ADT) induces macrophage migration inhibitory factor (MIF) upregulation, which in turn drives prostate cancer cell proliferation via upregulating AMPD2 expression, eventually contributing to the development of resistance to ADT. [The Prostate]
|
|
|
|
|
|
|
|
Less traditional transcriptional roles for androgen receptor (AR), such as those impacting non-coding RNAs as well as transcription-independent roles that include AR-dependent splicing programs and translation control have been recognized to contribute to aggressive CRPC features and treatment resistance.
[Oncogene]
|
|
|
|
|
|
The authors take a broad view of both prostate epithelial cell-intrinsic and cell-extrinsic factors that change with age and are likely to contribute to age-related risk of prostate tumorigenesis. For each factor, they discuss the impact of these age-related changes on cancer risk. [Endocrine-Related Cancer]
|
|
|
|
|
|
|
|
The NRG Oncology study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed accrual and met its accrual milestone of 2,478 patients approximately two years earlier than the trial’s anticipated accrual completion date. [NRG Oncology]
|
|
|
|
|
|
FibroGen, Inc. announced the initiation of the Phase II monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46-expressing cancer lesions in patients with metastatic CRPC. [FibroGen, Inc.]
|
|
|
|
|
|
|
|
November 2-4, 2025 Los Angeles, California, United States
|
|
|
|
|
|
|
|
|
|
|
University College London – London, England, United Kingdom
|
|
|
|
|
|
|
University of Miami Desai Sethi Urology Institute – Miami, Florida, United States
|
|
|
|
|
|
|
King’s College London – London, England, United States
|
|
|
|
|
|
|
Henry Ford Health + Michigan State – Detroit, Michigan, United States
|
|
|
|
|
|
|
University of Bristol – Bristol, England, United Kingdom
|
|
|
|
|
|